DK1613296T3 - Fremgangsmåder til behandling af Parkinsons sygdom - Google Patents

Fremgangsmåder til behandling af Parkinsons sygdom

Info

Publication number
DK1613296T3
DK1613296T3 DK04726590T DK04726590T DK1613296T3 DK 1613296 T3 DK1613296 T3 DK 1613296T3 DK 04726590 T DK04726590 T DK 04726590T DK 04726590 T DK04726590 T DK 04726590T DK 1613296 T3 DK1613296 T3 DK 1613296T3
Authority
DK
Denmark
Prior art keywords
disease
methods
treating parkinson
parkinson
treating
Prior art date
Application number
DK04726590T
Other languages
Danish (da)
English (en)
Inventor
Fariello Ruggero
Carlo Cattaneo
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1613296(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Application granted granted Critical
Publication of DK1613296T3 publication Critical patent/DK1613296T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04726590T 2003-04-11 2004-04-08 Fremgangsmåder til behandling af Parkinsons sygdom DK1613296T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
PCT/IB2004/001408 WO2004089353A2 (en) 2003-04-11 2004-04-08 Methods for treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
DK1613296T3 true DK1613296T3 (da) 2009-10-05

Family

ID=33159845

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09154864.4T DK2070526T3 (da) 2003-04-11 2004-04-08 Fremgangsmåder til behandling af parkinsons sygdom
DK04726590T DK1613296T3 (da) 2003-04-11 2004-04-08 Fremgangsmåder til behandling af Parkinsons sygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09154864.4T DK2070526T3 (da) 2003-04-11 2004-04-08 Fremgangsmåder til behandling af parkinsons sygdom

Country Status (28)

Country Link
US (3) US8283380B2 (ko)
EP (2) EP1613296B1 (ko)
JP (2) JP2006522800A (ko)
KR (2) KR20110070929A (ko)
CN (2) CN1771030A (ko)
AR (1) AR044007A1 (ko)
AT (1) ATE435012T1 (ko)
AU (1) AU2004228782B2 (ko)
BR (1) BRPI0409364A (ko)
CA (1) CA2523188C (ko)
CY (3) CY1109295T1 (ko)
DE (1) DE602004021790D1 (ko)
DK (2) DK2070526T3 (ko)
ES (2) ES2454272T3 (ko)
FR (1) FR15C0054I2 (ko)
HU (1) HUS1500043I1 (ko)
IL (2) IL171331A (ko)
LU (1) LU92782I2 (ko)
MX (1) MXPA05010873A (ko)
NL (1) NL300752I2 (ko)
NO (3) NO334316B1 (ko)
NZ (1) NZ542910A (ko)
PL (2) PL2070526T3 (ko)
PT (2) PT2070526E (ko)
RU (1) RU2342929C2 (ko)
SI (2) SI1613296T1 (ko)
TW (1) TWI340640B (ko)
WO (1) WO2004089353A2 (ko)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
ES2253579T3 (es) 2001-09-03 2006-06-01 Newron Pharmaceuticals S.P.A. Composicion farmaceutica que comprende gabapentina o un analogo suyo y una alfa-aminoamida y su uso analgesico.
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
JP5319920B2 (ja) * 2004-09-10 2013-10-16 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ナトリウムおよび／またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための（ハロベンジルオキシ）ベンジルアミノ−プロパンアミドの使用
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US8772346B2 (en) 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
DK1963280T3 (en) * 2005-12-22 2015-12-14 Newron Pharm Spa 2-phenylethylamine derivatives by calcium and / or sodium channel
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
MX2008015704A (es) 2006-06-19 2009-01-09 Newron Pharm Spa Proceso para la produccion de 2-[4-(3-y 2-fluoro benciloxi) bencilamino]propanamidas.
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
WO2008151702A1 (en) 2007-06-15 2008-12-18 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
WO2009054964A1 (en) * 2007-10-22 2009-04-30 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
EA030250B1 (ru) 2007-12-11 2018-07-31 Ньюрон Фармасьютикалс С.П.А. Применение 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты и содержащие их фармацевтические композиции
JP5736175B2 (ja) * 2007-12-19 2015-06-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 精神障害の治療に有用なα−アミノアミド誘導体
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
NZ589470A (en) * 2008-06-02 2012-08-31 Generics Uk Ltd A process for the preparation of rasagiline and its analogues
AU2009254927B2 (en) 2008-06-02 2014-03-13 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
EP2303330B2 (en) * 2008-06-06 2021-06-16 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
CN102065687A (zh) * 2008-06-13 2011-05-18 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
AU2011246707B2 (en) 2010-04-27 2014-11-20 Newron Pharmaceuticals S.P.A. Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers
UA103851C2 (en) 2010-04-30 2013-11-25 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Propylaminoindan transdermal composition
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
WO2013081685A1 (en) 2011-08-19 2013-06-06 The Trustees Of Princeton University C-halogen bond formation
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
US10918607B2 (en) 2012-11-02 2021-02-16 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
JP2016523918A (ja) 2013-06-27 2016-08-12 シーダーズ−サイナイ メディカル センター 神経変性状態の予防および治療のためのアドレナリン受容体拮抗薬
JP2017513866A (ja) * 2014-04-21 2017-06-01 サイヴィタス セラピューティックス，インコーポレイテッド パーキンソン病の運動症状変動の迅速な緩和
AU2015324914B2 (en) 2014-10-02 2018-10-04 Neurobiogen Co., Ltd. Alpha-aminoamide derivative compound and pharmaceutical composition containing the same
WO2017032874A1 (en) * 2015-08-27 2017-03-02 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
WO2017161155A1 (en) * 2016-03-17 2017-09-21 The Johns Hopkins University Methods for preventing or treating parkinson's disease by the farnesylation of paris
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (en) * 2017-01-14 2020-12-09 Neurrx, SPC METHOD OF USING HUMAN EXCREMENTS AND SECRETS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
WO2019036624A1 (en) * 2017-08-17 2019-02-21 Gu Zi Qiang MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
MX2020004403A (es) 2017-11-02 2020-08-06 Zambon Spa Composiciones farmaceuticas que comprenden safinamida.
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
US20230028539A1 (en) * 2019-12-06 2023-01-26 Shanghai Pharmaceuticals Holding Co., Ltd. Pharmaceutical composition, complementary kit and application thereof
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
WO2022047298A1 (en) * 2020-08-31 2022-03-03 Purdue Pharma L.P. Compositions and methods for levodopa delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
JP2736103B2 (ja) 1988-03-01 1998-04-02 ヴァルター・ビルクマイヤー パーキンソン症候群の治療用医薬、およびその製造方法
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
CN1771030A (zh) 2006-05-10
NO20054640D0 (no) 2005-10-10
NL300752I2 (ko) 2016-07-05
TWI340640B (en) 2011-04-21
ATE435012T1 (de) 2009-07-15
NO2015018I1 (no) 2015-08-03
EP2070526B1 (en) 2014-02-26
RU2342929C2 (ru) 2009-01-10
CA2523188A1 (en) 2004-10-21
KR20060010745A (ko) 2006-02-02
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
NZ542910A (en) 2007-10-26
WO2004089353A2 (en) 2004-10-21
CN102274517B (zh) 2018-08-31
MXPA05010873A (es) 2006-03-21
SI2070526T1 (sl) 2014-05-30
CA2523188C (en) 2012-09-25
US20130053368A1 (en) 2013-02-28
PT2070526E (pt) 2014-03-31
SI1613296T1 (sl) 2009-10-31
RU2005131422A (ru) 2006-04-27
NO335537B1 (no) 2014-12-22
FR15C0054I1 (fr) 2015-11-09
PL2070526T3 (pl) 2014-08-29
NO20131417L (no) 2005-12-09
US8283380B2 (en) 2012-10-09
CY1109295T1 (el) 2014-07-02
JP2013067647A (ja) 2013-04-18
DE602004021790D1 (de) 2009-08-13
US9492410B2 (en) 2016-11-15
IL216403A0 (en) 2011-12-29
US8901176B2 (en) 2014-12-02
KR101129015B1 (ko) 2012-04-20
ES2454272T3 (es) 2014-04-10
JP2006522800A (ja) 2006-10-05
ES2326373T3 (es) 2009-10-08
TW200505423A (en) 2005-02-16
EP1613296A2 (en) 2006-01-11
CY2015025I1 (el) 2016-04-13
EP2070526A1 (en) 2009-06-17
AU2004228782B2 (en) 2010-05-20
HUS1500043I1 (hu) 2018-11-28
CY1115286T1 (el) 2017-01-04
NO2015018I2 (no) 2015-07-23
AR044007A1 (es) 2005-08-24
US20150150833A1 (en) 2015-06-04
PL1613296T3 (pl) 2009-12-31
IL171331A (en) 2012-03-29
PT1613296E (pt) 2009-07-30
NO334316B1 (no) 2014-02-03
KR20110070929A (ko) 2011-06-24
DK2070526T3 (da) 2014-03-24
IL216403A (en) 2015-01-29
CY2015025I2 (el) 2016-04-13
WO2004089353A8 (en) 2005-09-01
AU2004228782A1 (en) 2004-10-21
EP1613296B1 (en) 2009-07-01
CN102274517A (zh) 2011-12-14
BRPI0409364A (pt) 2006-04-25
WO2004089353A3 (en) 2004-12-16
LU92782I2 (fr) 2015-09-22
FR15C0054I2 (fr) 2018-01-26

Similar Documents

Publication Publication Date Title
DK1613296T3 (da) Fremgangsmåder til behandling af Parkinsons sygdom
DK1443955T3 (da) PDGF-BB til behandling af Parkinsons sygdom
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK2821085T3 (da) Rna-interferens til behandling af "gain-of-function"-forstyrrelser
DE602004019373D1 (de) Bilderzeugungsverfahren
FI20020479A0 (fi) Pintakäsittelyprosessi
DE602004002056D1 (de) Fixation d'un coussin gonflable
DE602004000916D1 (de) Rückkopplungsgeregeltes Spannsystem
DK1628988T3 (da) Hidtil ukendte 14- og 15 leddede ringforbindelser
DE50207780D1 (de) Kalander
FR2851326B3 (fr) Hotte d'extraction
DK1639139T3 (da) Fremgangsmåder til påvisning af Alzheimers sygdom
DK1699747T3 (da) Fremgangsmåde til fremstilling af 2,3-cis-substitueret 2-arylpropenaler
FR2892012B1 (fr) Procede d'epilation
FR2852042B1 (fr) Piece d'aretier
DE50209339D1 (de) Kalander
ES1054316Y (es) "forjado nervado"
SE0201072D0 (sv) Homing process
NO20033536D0 (no) Snus-porsjonerer
ITPT20030007U1 (it) "mybox"
FI5888U1 (fi) Kalanteri
ITRC20030003U1 (it) "portamonete"